Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer    BAYN   DE000BAY0017

My previous session
Most popular
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

Bayer : Halts Phase 3 Study on New Xarelto Indication

share with twitter share with LinkedIn share with facebook
share via e-mail
10/06/2017 | 08:44am CEST
   By Sarah Sloat 

Bayer AG (>> Bayer) said late Thursday it halted a phase 3 study for the use of blood-thinning drug Xarelto because it didn't show improved efficacy compared with another treatment using aspirin.

The Navigate Esus study was testing Xarelto for the secondary prevention of strokes and systemic embolism in patients who recently had an embolic stroke of undetermined source.

Researchers stopped the trial early because the Xarelto and aspirin arms of the study showed comparable efficacy, and there was little chance of an overall benefit if it were completed, the German pharmaceutical and chemicals company said.

"While bleeding rates were low overall, an increase in bleeding was observed in the [Xarelto] arm compared to the low-dose aspirin arm," Bayer said.

Xarelto, also known as rivaroxaban, is a prescription anticoagulant which been approved for seven indications. The drug contributed just over 2.9 billion euros ($3.4 billion) in sales to Bayer's pharmaceutical division last year.

The drug was developed jointly by Bayer and Janssen Pharmaceuticals, a unit of Johnson & Johnson (>> Johnson & Johnson). It is marketed outside the U.S. by Bayer and within the U.S. by Janssen.

Write to Sarah Sloat at sarah.sloat@wsj.com

Stocks mentioned in the article : Bayer, Johnson & Johnson
Stocks mentioned in the article
ChangeLast1st jan.
BAYER -1.15% 77.38 Delayed Quote.-23.72%
JOHNSON & JOHNSON 2.12% 139.46 Delayed Quote.-4.19%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BAYER
10/17BAYER : Immediate support for earthquake victims in Indonesia
10/17BAYER : biological crop protection product combats bacterial and fungal crop dis..
10/17Beset by copies, Roche gets sales boost from China
10/16BAYER : stock sets seven-year record after favourable court ruling
10/16BAYER : supports farmers with a wide range of integrated agronomic solutions
10/16JURORS : Don't throw out $289M weed killer cancer verdict
10/15BAYER : Could Outsource Some Drug Research -Reuters
10/15BAYER : may outsource some drug research - works council
10/11BAYER : Shares Jump in Germany After Roundup Ruling
10/11BAYER : Shares Jump After U.S. Court Calls for New Roundup Trial
More news
News from SeekingAlpha
10/17COVESTRO : Ultimate Buying Opportunity With A FCF Yield Of 16.0% 
10/15BAYER : A Pleading For Glyphosate 
10/14CATALYST BIOSCIENCES : Rare Risk/Reward Opportunity 
10/12Key events next week - healthcare 
10/11BAYER AG : A Good Opportunity To Buy The Dips 
Financials (€)
Sales 2018 39 290 M
EBIT 2018 7 500 M
Net income 2018 4 932 M
Debt 2018 39 300 M
Yield 2018 3,68%
P/E ratio 2018 14,95
P/E ratio 2019 14,69
EV / Sales 2018 2,84x
EV / Sales 2019 2,30x
Capitalization 72 161 M
Duration : Period :
Bayer Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 99,5 €
Spread / Average Target 29%
EPS Revisions
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER-23.72%81 882
JOHNSON & JOHNSON-4.19%359 141
PFIZER20.87%256 643
NOVARTIS0.07%212 170
ROCHE HOLDING LTD.-4.56%204 777
MERCK AND COMPANY23.44%185 661